Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Announces Launch Of DSCSA Supply Chain Security Pilot Program

Executive Summary

FDA is accepting applications from the pharmaceutical industry to pilot electronic tracking systems for prescription drugs in preparation for a Nov. 27, 2023, implementation deadline.

You may also be interested in...



DSCSA Pilot Used Blockchain To Trace Drug Through 'Last Mile' of Supply Chain

A blockchain application for mobile devices was successfully piloted to conduct real-time tracking of a high-cost drug through the “last mile” of the supply chain to the point of dispensing. Such a tool can be useful for manufacturers in tracing their products through the supply chain and complying with a forthcoming mandate of the US FDA Drug Supply Chain Security Act (DSCSA).

DSCSA Pilot Finds Blockchain Feasible For Meeting Track-And-Trace Requirements

A pharmaceutical industry consortium gives the thumbs up for using blockchain technology to track and trace products through the supply chain to meet DSCSA mandate, yet says new standards are necessary.

Florida’s Importation Plan: 45% Markup On Canadian Prices Expected To Cover Costs And Produce Savings

Plan will be limited to purchases by state agencies and organizations. Drugs considered eligible for importation include treatments for HIV, multiple sclerosis and epilepsy.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS124723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel